Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure

Blood (2016) 127 (13): 1656–1665.

https://doi.org/10.1182/blood-2015-10-676924

Published: 2016

Includes: Supplemental data

Journal Articles

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial

Blood (2015) 126 (23): 737.

https://doi.org/10.1182/blood.V126.23.737.737

Published: 2015

Journal Articles

Trends of Venous Thromboembolism (VTE) and Risk Factors for Developing VTE in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT) in children’s Hospitals-a PHIS Database Study

Surabhi Batra, MBBS, Lawrence Salud, Patti Duda, David Bertoch, MBA, Reggie Duerst, MD, Matt Hall, PhD, Anjali Sharathkumar, MDMS

Blood (2014) 124 (21): 1474.

https://doi.org/10.1182/blood.V124.21.1474.1474

Published: 2014

Journal Articles

Robust Immune Reconstitution in Children with Severe Primary Immunodeficiency after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation

William T. Tse, MD PhD, Jessica Ward, MSN, cPNP, Jennifer Schneiderman, MD MS, Sonali Chaudhury, MD, Ramsay Fuleihan, MD, Reggie Duerst, MD, Morris Kletzel, MD

Blood (2014) 124 (21): 3923.

https://doi.org/10.1182/blood.V124.21.3923.3923

Published: 2014

Journal Articles

The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation

Michael J Eckrich, MD, MPH, Jennifer Le-Rademacher, PhD, J. Douglas Rizzo, MD, MS, K. Scott Baker, MD, MS, Deepika Bhatla, MD, David K. Buchbinder, M.D., M.S.H.S., Kenneth R. Cooke, MD, Reggie Duerst, MD, Andrew Gilman, MD, Haydar Frangoul, MD, Neena Kapoor, MD, Nancy A. Kernan, MD, Michael Verneris, MD, Mary Eapen, MBBS

Blood (2012) 120 (21): 762.

https://doi.org/10.1182/blood.V120.21.762.762

Published: 2012

Journal Articles

Does Methotrexate Affect Transplant Outcomes? Transplant Related Mortality (TRM), Engraftment, Graft Vs. Host Disease (GvHD), Overall Survival (OS) and Event Free Survival (EFS) in 142 Consecutive Pediatric Cord Blood Transplants (CBT) At Children's Memorial Hospital (CMH)

Morris Kletzel, MD, Mebhoob Merchant, Nazneen Merchant, CRA, Alfred Rademaker, STATISTICIAN PHD, Reggie Duerst, MD, Sonali Chaudhury, M.D., Jennifer Schneiderman, MD, MS, William T. Tse, MD, PhD

Blood (2011) 118 (21): 3028.

https://doi.org/10.1182/blood.V118.21.3028.3028

Published: 2011

Journal Articles

Chronic Graft-Versus-Host Disease and Its Association with Treatment-Related Mortality, Relapse, Leukemia-Free and Overall Survival After Umbilical Cord Blood Transplantation (UCBT) In Children and Adolescents with Acute Leukemia

Mary Eapen, MBBS, Tao Wang, PhD, Joanne Kurtzberg, MD, Stephanie J. Lee, Reggie Duerst, MD, Mukta Arora, MD, Carmem Bonfim, MD, Michel Duval, MD, Gretchen Eames, MD, Karin Tiedemann, MBBS, FRACP, Daniel J. Weisdorf, MD, John E. Wagner, MD

Blood (2010) 116 (21): 213.

https://doi.org/10.1182/blood.V116.21.213.213

Published: 2010

Journal Articles

Pediatric Myelodysplastic Syndromes and Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT): A Single Center Perspective.

Jeffrey R. Andolina, MD, Morris Kletzel, MD, David Jacobsohn, MD, ScM, William T. Tse, MD, PhD, Jennifer Schneiderman, MD, MS, Reggie Duerst, MD, Irene Helenowski, Sonali Chaudhury, M.D.

Blood (2009) 114 (22): 1780.

https://doi.org/10.1182/blood.V114.22.1780.1780

Published: 2009

Journal Articles

Age-Dependent Pharmacokinetic Profile of Single Daily Dose Intravenous Busulfan in Children Undergoing Reduced-Intensity Conditioning Stem Cell Transplantation

William T. Tse, MD, PhD, Reggie Duerst, MD, Jennifer Schneiderman, MD, MS, Sonali Chaudhury, M.D., David Jacobsohn, MD, Morris Kletzel, MD

Blood (2008) 112 (11): 796.

https://doi.org/10.1182/blood.V112.11.796.796

Published: 2008

Journal Articles

Potential Increase in Graft Failure Risk after Reduced Intensity Conditioning Stem Cell Transplant (RIT) Using Umbilical Cord Blood for Children with Primary Immunodeficiency.

Jessica Guarino, MSN, MPH, Morris Kletzel, M.D., Reggie Duerst, M.D., David Jacobsohn, M.D., M.S., Jennifer Schneiderman, M.D., M.S., William T. Tse, M.D., Ph.D.

Blood (2007) 110 (11): 2006.

https://doi.org/10.1182/blood.V110.11.2006.2006

Published: 2007

Journal Articles

Reduced Intensity Conditioning (RIC) and Hematopoietic Stem Cell Transpalntation (HSCT) Utilizing Extracorporeal Photopheresis (ECP), Fludarabine, and Targeted Dose Busulfan in Children.

Jennifer Schneiderman, MD, MS, Reggie Duerst, MD, Kim Campbell, PhD, Amy Krutsick, MS, William Tse, MD, PhD, Kimberly Thormann, CPNP, Morris Kletzel, MD, David A. Jacobsohn, MD

Blood (2006) 108 (11): 5307.

https://doi.org/10.1182/blood.V108.11.5307.5307

Published: 2006

Journal Articles

Efficacy of Reduced Intensity Conditioning (RIC) with FLU-BU-ATG and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Pediatric ALL.

Reggie Duerst, MD, David Jacobsohn, MD, William T. Tse, MD, PhD, Morris Kletzel, MD

Blood (2004) 104 (11): 2314.

https://doi.org/10.1182/blood.V104.11.2314.2314

Published: 2004

Journal Articles

Single Daily Dose of I.V. Busulfan (BU) in Pediatric Patients. Feasibility, Pharmacokinetics (PK) and Toxicity.

Morris Kletzel, M.D., David Jacobsohn, M.D., William Tse, M.D., Reggie Duerst, M.D.

Blood (2004) 104 (11): 1151.

https://doi.org/10.1182/blood.V104.11.1151.1151

Published: 2004

NARROW

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial

Trends of Venous Thromboembolism (VTE) and Risk Factors for Developing VTE in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT) in children’s Hospitals-a PHIS Database Study

Robust Immune Reconstitution in Children with Severe Primary Immunodeficiency after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation

The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation

Does Methotrexate Affect Transplant Outcomes? Transplant Related Mortality (TRM), Engraftment, Graft Vs. Host Disease (GvHD), Overall Survival (OS) and Event Free Survival (EFS) in 142 Consecutive Pediatric Cord Blood Transplants (CBT) At Children's Memorial Hospital (CMH)

Chronic Graft-Versus-Host Disease and Its Association with Treatment-Related Mortality, Relapse, Leukemia-Free and Overall Survival After Umbilical Cord Blood Transplantation (UCBT) In Children and Adolescents with Acute Leukemia

Pediatric Myelodysplastic Syndromes and Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT): A Single Center Perspective.

Age-Dependent Pharmacokinetic Profile of Single Daily Dose Intravenous Busulfan in Children Undergoing Reduced-Intensity Conditioning Stem Cell Transplantation

Potential Increase in Graft Failure Risk after Reduced Intensity Conditioning Stem Cell Transplant (RIT) Using Umbilical Cord Blood for Children with Primary Immunodeficiency.

Reduced Intensity Conditioning (RIC) and Hematopoietic Stem Cell Transpalntation (HSCT) Utilizing Extracorporeal Photopheresis (ECP), Fludarabine, and Targeted Dose Busulfan in Children.

Efficacy of Reduced Intensity Conditioning (RIC) with FLU-BU-ATG and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Pediatric ALL.

Single Daily Dose of I.V. Busulfan (BU) in Pediatric Patients. Feasibility, Pharmacokinetics (PK) and Toxicity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only